{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:06:47Z","timestamp":1793390807135,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T00:00:00Z","timestamp":1755388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clgc.2025.102417","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T08:24:43Z","timestamp":1755505483000},"page":"102417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1872-6307","authenticated-orcid":false,"given":"Ryan D.","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clgc.2025.102417_bib0001","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"New Engl J Med"},{"issue":"7","key":"10.1016\/j.clgc.2025.102417_bib0002","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jnci\/djt015","article-title":"Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy","volume":"105","author":"Apolo","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"10.1016\/j.clgc.2025.102417_bib0003","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1002\/cncr.28146","article-title":"Nomogram for predicting survival in patients with unresectable and\/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy","volume":"119","author":"Galsky","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2025.102417_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100090","article-title":"Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study","volume":"6","author":"Ruiz-Ba\u00f1obre","year":"2021","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.clgc.2025.102417_bib0005","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41571-023-00734-5","article-title":"Cancer-associated cachexia \u2014 Understanding the tumour macroenvironment and microenvironment to improve management","volume":"20","author":"Argil\u00e9s","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102417_bib0006","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.critrevonc.2010.10.004","article-title":"Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer","volume":"80","author":"Blum","year":"2011","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102417_bib0007","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102417_bib0008","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/jcsm.12776","article-title":"Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross-sectional survey (NutriAgeCancer)","volume":"12","author":"Poisson","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.clgc.2025.102417_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115895","article-title":"Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma","volume":"10","author":"Fukushima","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.clgc.2025.102417_bib0010","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.31557\/APJCP.2019.20.10.2995","article-title":"Skeletal muscle mass reduction velocity as a simple prognostic indicator for patients with metastatic urothelial carcinoma receiving second-line chemotherapy","volume":"20","author":"Nagai","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"10.1016\/j.clgc.2025.102417_bib0011","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/diagnostics10050310","article-title":"Clinical impact of sarcopenia and inflammatory\/nutritional markers in patients with unresectable metastatic urothelial carcinoma treated with Pembrolizumab","volume":"10","author":"Shimizu","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"10.1016\/j.clgc.2025.102417_bib0012","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ajco.13666","article-title":"Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab","volume":"18","author":"Yamamoto","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102417_bib0013","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","article-title":"ESPEN practical guideline: clinical nutrition in cancer","volume":"40","author":"Muscaritoli","year":"2021","journal-title":"Clin Nutr"},{"issue":"2","key":"10.1016\/j.clgc.2025.102417_bib0014","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10120-015-0481-4","article-title":"Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer","volume":"19","author":"Ock","year":"2016","journal-title":"Gastric Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2025.102417_bib0015","doi-asserted-by":"crossref","first-page":"e1538","DOI":"10.1002\/onco.13836","article-title":"Early weight loss as a prognostic factor in patients with advanced gastric cancer: analyses from REGARD, RAINBOW, and RAINFALL phase III studies","volume":"26","author":"Mansoor","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.clgc.2025.102417_bib0016","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ncp.10588","article-title":"The use of visceral proteins as nutrition markers: an ASPEN position paper","volume":"36","author":"Evans","year":"2021","journal-title":"Nutrit Clin Pract"},{"issue":"3","key":"10.1016\/j.clgc.2025.102417_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081480","article-title":"Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study","volume":"14","author":"Labidi","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.clgc.2025.102417_bib0018","article-title":"Impact of age at diagnosis of bladder cancer on survival: a surveillance, epidemiology, and end results-based study 2004-2015","volume":"30","author":"Lin","year":"2023","journal-title":"Ca Contr"},{"issue":"24","key":"10.1016\/j.clgc.2025.102417_bib0019","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","article-title":"Ponsegromab for the treatment of cancer cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"New Engl J Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732500117X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732500117X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:07:59Z","timestamp":1770671279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732500117X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S155876732500117X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102417","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102417"}}